Objectives: To compare the effect of tigecycline monotherapy, a first-in-class, expanded broad spectrum glycylcycline, with the combination of vancomycin and aztreonam (V + A) in the treatment of complicated skin and skin structure infections (cSSSI). Methods: A phase 3, double-blind study conducted in 8 countries enrolled adults with cSSSI who required intravenous (IV) antibiotic therapy for !5 days. Patients were randomly assigned (1:1) to receive either tigecycline or V + A for up to 14 days. Primary endpoint was the clinical cure rate at the test-of-cure visit. Secondary endpoints included microbiologic efficacy and in vitro susceptibility to tigecycline of bacteria that cause cSSSI. Safety was assessed by physical examination, laboratory analyses, and adverse event reporting. Results: A total of 596 patients were screened for enrollment, 573 were analyzed for safety, 537 were included in the clinical modified intent-to-treat (c-mITT) population,
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Introduction
Complicated skin and skin structure infections (cSSSI) are often polymicrobial in origin, occurring in patients with preexisting skin lesions or underlying comorbid conditions. Patients with cSSSI frequently require hospitalization and parenteral antibiotic therapy. 1 With the emergence of multidrug-resistant organisms during the last decade, therapeutic options have become limited, especially when resistance develops to previously susceptible organisms. 2, 3 Since the early 1980s, the number of newly approved antibacterial agents in the USA has decreased substantially, and relatively few are currently in development. 4 Thus, there is an increasing clinical need for new therapies that are effective against resistant strains of microorganisms.
Tigecycline is a broad spectrum glycylcycline antibiotic 5 with potent inhibition of bacterial protein synthesis and cell growth. 6 Tigecycline was designed to circumvent two common drug-resistance mechanisms of bacteria: efflux and ribosomal protection. 7 In vitro studies have demonstrated strong activity against a wide range of Gram-positive and Gramnegative pathogens, including methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively), penicillin-resistant Streptococcus pneumoniae, Escherichia coli, Hemophilus influenzae, Enterococcus faecalis, Enterococcus faecium, Moraxella catarrhalis, Bacteroides spp., and Neisseria gonorrheae. [8] [9] [10] [11] A preliminary, phase 2, randomized study of hospitalized patients with cSSSI demonstrated the clinical and microbiologic efficacy of tigecycline at both 50 mg and 25 mg doses. 12 Further, the phase 2 study showed that tigecycline was well tolerated and had a favorable pharmacokinetic profile. Tigecycline has demonstrated activity against a broad spectrum of pathogens frequently associated with cSSSI, including Gram-positive (Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis) and Gramnegative (E. coli) bacteria. 8, [13] [14] [15] Tigecycline's activity against resistant organisms, as well as its significant coverage of both Gram-positive and Gram-negative bacteria, may provide a valuable therapeutic alternative in treating patients with cSSSI. Based on the results of phase 1 and phase 2 clinical studies, a large phase 3 trial was conducted to assess the safety and efficacy of tigecycline (50 mg) plus placebo compared with the combination of vancomycin and aztreonam (V + A) in treating patients with cSSSI. Vancomycin is active against a wide variety of Gram-positive pathogens and is indicated for the treatment of serious or severe skin infections, including those caused by susceptible strains of MRSA. 16 Vancomycin, however, lacks appreciable activity against Gram-negative microorganisms, and thus aztreonam was added to the comparator regimen. Aztreonam is indicated for treatment of cSSSI and other infections caused by susceptible Gram-negative microorganisms. 17 We conducted the present phase 3, double-blind, randomized trial to compare the effect of tigecycline monotherapy with the combination of V + A in hospitalized patients with skin and skin structure infections.
Methods

Patient population
Men and women !18 years of age who required intravenous (IV) antibiotic therapy for !5 days for known or suspected cSSSI were eligible for study participation. Complicated SSSI included infections involving deep soft tissue or requiring significant surgical intervention, including extensive cellulitis of at least 10 cm in width or length, or those associated with a significant underlying disease state 252 S. Sacchidanand et al. 397 were clinically evaluable (CE), and 228 were microbiologically evaluable (ME). At test-of-cure, cure rates were similar between tigecycline and V + A groups in the CE population (82.9% versus 82.3%, respectively) and in the c-mITT population (75.5% versus 76.9%, respectively). Microbiologic eradication rates (subject level) at test-ofcure in the ME population were also similar between tigecycline and V + A. Frequency of adverse events was similar between groups, although patients receiving tigecycline had higher incidence of nausea, vomiting, dyspepsia, and anorexia, while increased ALT/SGPT, pruritis, and rash occurred significantly more often in V + A-treated patients.
Conclusions: This study demonstrates that the efficacy of tigecycline monotherapy for the treatment of patients with cSSSI is statistically noninferior to the combination of V + A. 
Study design
This randomized, double-blind, phase 3 trial was designed to compare the safety and efficacy of tigecycline monotherapy with the combination of V + A in patients with cSSSI. The trial was conducted at 89 centers in 8 countries in North America, South America, and India (USA, Canada, Argentina, Chile, Guatemala, Mexico, Peru, and India). Each center received approval from its institutional review board or independent ethics committee, and all patients provided written informed consent. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
Patients were randomly assigned (1:1) to receive either tigecycline with placebo or the combination of V + A intravenously for up to 14 days. The randomization schedule was generated by the Biostatistics Department of Wyeth Research (Collegeville, PA, USA). Study medications were administered in a double-blind fashion or through an unblinded dispenser who did not participate in the direct evaluation of patient efficacy or safety endpoints.
Patients randomly assigned to tigecycline received an initial 100 mg dose, followed by 50 mg twice daily (approximately every 12 h) thereafter, in a volume of 250 mL normal saline infused over a 60 minute period. After each tigecycline infusion, patients received 100 mL normal saline placebo infused over another 60 minute period. Patients randomly assigned to V + A received twice-daily IV administration (approximately every 12 h) of 1 g vancomycin in 250 mL of normal saline over a 60 minute period, followed by 2 g aztreonam in 100 mL normal saline over another 60 minute period. Infusion bags and tubing were covered to obscure the color of tigecycline in solution in order to maintain the blind.
Patients were allowed to receive standard treatment for any stable, acute, or chronic medical condition. Wound irrigation with sterile water or saline solution, or topical antiseptics such as sulfadiazine, mafenide acetate, polyvidone iodine, chlorhexidine, hydrogen peroxide, or Dakin's solution was permitted. Patients could also receive daily débridements or operative procedures as necessary based on standard of care. However, the use of topical antibacterials, steroids, and any nonstudy antibacterials or other investigational therapies was prohibited.
Populations analyzed
Patients were initially screened for enrollment in the study, and those who met eligibility criteria were randomly assigned to treatment and comprised the intent-to-treat (ITT) population. The modified ITT (mITT) population consisted of patients in the ITT population who received at least one dose of study drug. Patients in the mITT population who had clinical evidence of cSSSI comprised the clinical mITT (c-mITT) population. The microbiologic mITT (m-mITT) population consisted of patients in the c-mITT population who had !1 isolate identified at baseline. The clinically evaluable (CE) population consisted of c-mITT patients who did not have Pseudomonas aeruginosa as a baseline primary isolate, did not receive concomitant antibiotics after the first dose of tigecycline, and who met criteria for either clinical cure or failure at the test-of-cure visit. The microbiologic evaluable (ME) population consisted of CE patients who had an identifiable primary isolate(s) that was susceptible to both study drugs and who had clinical and microbiologic outcomes (i.e., eradication, persistence, or superinfection) at the test-of-cure visit.
Efficacy endpoints
The primary efficacy endpoint was a clinical response in the CE and c-mITT populations at the test-of-cure visit. Clinical response was defined as cure (i.e., resolution or improvement of signs and symptoms of infection to the extent that no further antibacterial therapy was required), failure (i.e., lack of response necessitating additional antibacterial therapy, extirpative surgical intervention, death due to infection >2 days after randomization, discontinuation due to treatment-related adverse event, or receipt of >120% of prescribed treatment), or indeterminate (i.e., lost to follow-up, death <2 days after randomization or death not related to infection before test-of-cure visit, no clinical response at test-of-cure assessment).
Secondary efficacy variables included clinical responses (cure or failure) and microbiologic responses at the patient level (eradication, persistence, superinfection, indeterminate) and isolate level (eradication, persistence, indeterminate) for patients in the ME and m-mITT populations at the test-of-cure assessments.
Bacterial cultures were obtained from the primary site of infection and were sent to local microbiology laboratories for identification. Local laboratories tested aerobic isolates for susceptibility to V + A by their standard techniques and to tigecycline by disk diffusion. All isolates recovered were subcultured and sent to a central laboratory (Covance Central Laboratory Services Inc., Indianapolis, IN, USA) for isolate confirmation. Antimicrobial susceptibility testing was done by both the Kirby-Bauer disk diffusion method and by the microbroth dilution method to determine the minimum inhibitory concentration (MIC) using procedures published by the National Committee for Clinical Laboratory Standards (NCCLS). [18] [19] [20] Provisional MIC breakpoints for tigecycline were determined from microbiologic samples obtained in previous clinical investigations: 2 mg/mL for susceptible, 4 mg/mL for intermediate, and !8 mg/mL for resistant. MIC 50 and MIC 90 represent the minimal concentration of antibiotic that inhibited the growth of 50% and 90% of the isolates, respectively. Organisms isolated from baseline cultures were considered to be the primary baseline isolates based on the frequency with which those organisms are identified in the particular disease state.
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Safety evaluation
All patients who received at least one dose of study drug (mITT population) were evaluated for safety and were monitored for adverse events. Safety assessments included a physical examination and 12-lead electrocardiograms (ECGs) at baseline. At each scheduled evaluation, vital signs (temperature, heart rate, blood pressure) and clinical laboratory parameters (hematology, serum chemistry evaluations, and coagulation profiles) were assessed. Adverse events (AEs) and treatmentemergent AEs (TEAEs), i.e., AEs that occurred or worsened during treatment, were recorded throughout the study period. Because renal failure is a frequent complication of bacteremia in hospitalized patients, 26 vancomycin dosage could be adjusted according to creatinine clearance levels for patients with compromised renal function as suggested by the vancomycin label. 16 Serum creatinine levels were determined at baseline, on days 3, 7, and 14, or last day of therapy, and at the testof-cure visit. There was no requirement for monitoring vancomycin levels. For patients who required vancomycin dose adjustments, an unblinded dispenser, who did not participate in direct evaluation of the efficacy or safety endpoints and did not interact with the patients, performed the adjustments.
Statistical analyses
Clinical and microbiologic responses to tigecycline and V + A were evaluated by using a 2-sided 95% confidence interval (CI) for the true difference in efficacy (i.e., tigecycline response rate minus V + A response rate). Noninferiority was concluded if the lower limit of the 2-sided 95% CI for the difference in efficacy was no larger than À15%. For all subpopulation analyses (e.g., subgroup analyses, monomicrobial versus polymicrobial), an adjusted difference between treatment groups with its 95% CI was calculated from a generalized linear model with a binomial probability function and an identity link (SAS 1 Proc GENMOD). The method of Wilson 27 was used for endpoints involving comparisons of tigecycline and V + A with small sample sizes. The 'exact' method of Clopper and Pearson 28 was used to compute the 2-sided 95% CI for a single proportion. The level of significance was set at 0.05.
Results
A total of 573 patients received at least one dose of study drug (mITT population) and were evaluated for safety; 292 were randomly assigned to tigecycline and 281 were randomly assigned to V + A (Figure 1 ). Patients were well matched between groups, and statistically significant differences in demographic characteristics between treatment groups (Table 1) did not exist. In both treatment groups, the predominant clinical diagnosis was deep soft tissue infection (62.0%), followed by major abscesses (28.6%). Overall, 51.7% of infections were spontaneous in nature, 26.9% were caused by trauma, and 10.8% resulted from surgery. Approximately 30% of patients in each group had diabetes. Significant differences were not observed between groups in the mean number of study drug doses, days on therapy, or mean calculated creatinine clearance values.
Concomitant antibiotics were given to significantly more patients in the V + A group (45 patients, 16.0%) than in the tigecycline group (30 patients, 10.3%; p = 0.047). These primarily consisted of betalactam antibacterials (n = 22, 3.8%) and antibacterials for topical use (n = 21, 3.7%). Additionally, 6 patients in the V + A group and none in the tigecycline group received concomitant quinolone antibiotics. The use of concomitant antibiotics was considered before the data were unblinded when determining which patients were clinically evaluable.
Clinical outcomes
Test-of-cure assessments were performed within 12 to 92 days following the end of treatment. A total of 199 tigecycline-treated patients and 198 V + A-treated patients completed therapy and comprised the CE population. Breaking the blind was the most common reason for exclusion from the CE population (8.9%). However, the blind was not broken for failure to respond.
At the test-of-cure visit, cure rates were not significantly different between treatment groups in the CE population (Table 2 ); 82.9% of patients receiving tigecycline monotherapy were cured by the test-of-cure visit. This success rate was comparable with that in patients treated with the V + A combination (82.3%) and demonstrates that the efficacy of tigecycline monotherapy was statistically noninferior to the combination of V + A (difference tigecycline -V + A % (95% CI) = 0.6% (À7.4,8.6), pvalue for noninferiority <0.001, p-value for differences = 0.9816). Tigecycline also met the statistical criteria for noninferiority to V + A in the c-mITT population (difference tigecycline -V + A % (95% CI) = À1.5% (À9.0,6.1) p-value for noninferiority <0.001, p-value for differences = 0.7650). Specifically, in the CE and c-mITT populations, the lower limit of the 95% CI for the true difference between treatments was À7.4% and À9.0%, respectively, at test-of-cure visit. Results in the ME and m-mITT populations were consistent with findings of noninferiority of tigecycline in the CE and c-mITT populations (Table 2) . When analyzed by clinical diagnosis, such as soft tissue infections and major abscesses, cure rates were also comparable between groups (Table 3) . Tigecycline monotherapy was comparable with V + A in the subsets of patients with baseline diagnoses of diabetes, peripheral vascular disease, or bacteremia.
Microbiologic responses
Eradication rates at the patient level were comparable between treatment groups, demonstrating the noninferiority of tigecycline monotherapy to the combination of V + A in eradicating skin infections in the ME (Table 4 ) and m-mITT (data not shown) populations. Although differences in eradication rates between groups were adjusted for type of infection, these differences were similar to unadjusted differences. Because of the small sample size, microbiologic response of failures were pooled with a similar phase 3 study and analyzed. The results of this pooled analysis will be summarized in a separate manuscript. Eradication rates of selected primary baseline isolates commonly associated with cSSSI were high in both treatment groups (Table 5) ; for MRSA, eradication rates were 76.2% for the tigecycline group and 81.0% for the V + A group.
MIC testing was used to evaluate the sensitivity of the selected primary baseline isolates commonly associated with cSSSI and the sensitivity of other isolates to tigecycline, vancomycin, and aztreonam. Over the course of this study, there was no evidence of the development of decreased susceptibility to tigecycline. Although the number of isolates available for analysis was small, bacterial susceptibilities to tigecycline appeared to be consistent with clinical responses. MIC 90 values for tigecycline monotherapy were uniformly low for the most prevalent isolates, including MRSA and MSSA, compared with the V + A combination (Table 6 ).
Safety
Both tigecycline and V + A were well tolerated and the overall frequency of treatment-emergent adverse events was similar between treatment groups (Table 7) . Only a small percentage of patients discontinued treatment because of adverse events: 18 patients (6.2%) in the tigecycline group and 13 patients (4.6%) in the V + A group in the mITT 258 S. Sacchidanand et al. In this study, all E. faecalis primary isolates were susceptible to vancomycin.
population. Nausea was the most common adverse event that led to discontinuation of study therapy among tigecycline-treated patients, whereas pruritis and rash were the most common adverse events that led to discontinuation in the V + A group. Of note, patients receiving V + A had a significantly higher incidence of pruritis, rash, and elevated ALT/SGPT levels compared with patients receiving tigecycline, whereas tigecycline-treated patients had significantly a higher incidence of nausea and vomiting, as well as anorexia and dyspepsia. No tigecycline-treated patient had a positive Clostridium difficile toxin assay, nor developed C. difficileassociated diarrhea. Five deaths occurred in the tigecycline group: two occurred more than one week after completion of therapy, one resulted from a prestudy condition (sepsis), one from unrelated complications (acute renal failure/cardiogenic shock) that occurred on the first and second day of therapy, and one resulted from a perforated ulcer. One death in the V + A group resulted from chronic obstructive pulmonary disease and congestive heart failure. No deaths were considered to be related to the use of the study drug. There were no clinically important changes from baseline in laboratory parameters, vital signs, or ECGs. Most laboratory changes were small, with means remaining within normal biologic ranges.
Discussion
This phase 3 randomized and double-blind trial demonstrated that the efficacy of tigecycline monotherapy was comparable with that of the combination of V + A in the treatment of patients with cSSSI. Subgroup analyses also found that success rates were similar with tigecycline monotherapy and combination V + A treatment among those patients with underlying diabetes, peripheral vascular disease, and bacteremia. In a previously reported phase 2 trial of hospitalized patients with cSSSI receiving 50 mg of tigecycline, patients had a clinical cure rate of 74% at test-of-cure assessment. 12 Although similar to the phase 2 trial results, the cure rate in the present phase 3 study is higher (82.9%) in the clinically evaluable population (Table 2) .
Tigecycline monotherapy was statistically noninferior to the combination of V + A, based on the lower boundary of the 2-sided CI (À7.4%) in the CE population for the difference in cure rate. Noninferiority of tigecycline to V + A was demonstrated by cure rates in the CE and c-mITT populations, by microbiologic responses of patients in the ME and m-mITT populations, and by microbiologic efficacy . During the study period, there was no evidence of the development of decreased susceptibility to tigecycline. Tigecycline and V + A were shown to be safe and well tolerated. Patients receiving the V + A combination experienced significantly higher incidences of pruritis, rash, and elevated levels of ALT/SGPT than patients receiving tigecycline monotherapy. Although the incidence of nausea and vomiting was significantly higher in tigecycline-treated patients, the severity was mild to moderate, and most patients did not discontinue treatment because of these events. An earlier report demonstrated that patient tolerance of tigecycline was improved when the drug was administered with food. 29 Tigecycline offers potential advantages over other parenterally administered antimicrobial agents because of its expanded spectrum of coverage against Gram-positive, anaerobic, Gram-negative, and multiply antimicrobial resistant microorganisms. The current standard of care for cSSSI may require an approach using either a very broad spectrum antimicrobial agent or multiple agents used in combination in order to provide antibacterial activity against both Gram-positive and Gram-negative isolates. 30, 31 Unlike vancomycin, tigecycline's spectrum of antibacterial activity does not cause it to require additional antimicrobial agents for Gram-negative coverage. Since tigecycline monotherapy provides activity against Gram-positive and Gram-negative microorganisms as well as anaerobes and certain antimicrobial resistant pathogens, 8, [13] [14] [15] [32] [33] [34] [35] only one antimicrobial agent needs to be administered. Compared with the V + A combination treatment, tigecycline monotherapy appears to be safe and efficacious in the treatment of patients with cSSSI and is a promising agent for the treatment of cSSSI.
These results were presented in part at the 11th International Symposium on Staphylococci & Staphylococcal Infections, October [24] [25] [26] [27] 2004 , Charleston, South Carolina, USA, Control #TH-13.
